Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 172 participants.

Also called NCT03257410

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 172 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03257410
Other papers using this trial's data
  • Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial Clinical journal of the American Society of Nephrology : CJASN, 2020-09-07 DOI, PubMed 32843372, PMC7480550 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03257410. Randomized; no masking; primary purpose treatment. Start 2017-09-29 (actual); primary completion 2018-10-27 (actual). Results posted on 2020-12-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients
Condition
End Stage Renal Disease
Intervention (Device)
Theranova 400 dialyzer
Intervention (Device)
Elisio-17H dialyzer
Lead sponsor
Vantive Health LLC (class: industry)
Collaborator
Baxter Healthcare Corporation (class: industry)

Record details

Record id
cardio:ct-nct03257410
Content hash
41d30be64ce0f94a817bc6386da019111b8ab3e8056012069beae0976ec31995